MA27181A1 - Derives de thiazole et d'oxazole qui modulent l'activite de ppar. - Google Patents

Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Info

Publication number
MA27181A1
MA27181A1 MA27839A MA27839A MA27181A1 MA 27181 A1 MA27181 A1 MA 27181A1 MA 27839 A MA27839 A MA 27839A MA 27839 A MA27839 A MA 27839A MA 27181 A1 MA27181 A1 MA 27181A1
Authority
MA
Morocco
Prior art keywords
ppar
activity
compounds
thiazole
modulate
Prior art date
Application number
MA27839A
Other languages
English (en)
Inventor
Xue-Min Cheng
Gary Frederick Filzen
Chitase Lee
Noe Ouano Erasga
Andrew George Geyer
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27181A1 publication Critical patent/MA27181A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

DEPOSANT Société dite : WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES US 7 Mars 2002 60/362,402 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de thiazole et d'oxazole qui modulent l'activité de PPAR La présente invention fait connaître des composés qui modifient l'activité de PPAR. La présente invention fait connaître également des sels pharmaceutiquement acceptables des composés, des compositions pharmaceutiquement acceptables comprenant les composés ou leurs sels, et des méthodes pour leur utilisation comme agents thérapeutiques à des fins de traitement ou de prévention de l'hyperlipidémie et de l'hypercholestérolémie chez un mammifère. La présente invention fait connaître également des procédés pour la préparation des composés décrits.
MA27839A 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar. MA27181A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
MA27181A1 true MA27181A1 (fr) 2005-01-03

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27839A MA27181A1 (fr) 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Country Status (29)

Country Link
US (1) US20030207924A1 (fr)
EP (1) EP1482935B1 (fr)
JP (1) JP2005528348A (fr)
KR (1) KR20040091693A (fr)
AP (1) AP2004003124A0 (fr)
AR (1) AR038881A1 (fr)
AT (1) ATE405260T1 (fr)
AU (1) AU2003206059A1 (fr)
BR (1) BR0308277A (fr)
CA (1) CA2478520A1 (fr)
CO (1) CO5601012A2 (fr)
DE (1) DE60323060D1 (fr)
EA (1) EA200400943A1 (fr)
EC (1) ECSP045285A (fr)
ES (1) ES2310650T3 (fr)
HN (1) HN2003000090A (fr)
IS (1) IS7377A (fr)
MA (1) MA27181A1 (fr)
MX (1) MXPA04007564A (fr)
NO (1) NO20044242L (fr)
OA (1) OA12780A (fr)
PA (1) PA8567801A1 (fr)
PE (1) PE20030989A1 (fr)
PL (1) PL372969A1 (fr)
TN (1) TNSN04168A1 (fr)
TW (1) TW200305403A (fr)
UY (1) UY27695A1 (fr)
WO (1) WO2003074050A1 (fr)
ZA (1) ZA200406068B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004240649A1 (en) * 2003-05-19 2004-12-02 Irm, Llc Immunosuppressant compounds and compositions
EP1737809B1 (fr) * 2004-02-27 2013-09-18 Amgen, Inc Composes, compositions pharmaceutiques et procedes d'utilisation dans le traitement de troubles metaboliques
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (fr) 2004-05-05 2005-11-10 Novo Nordisk A/S Nouveaux composes, leur preparation et leur utilisation
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2005115384A2 (fr) * 2004-05-25 2005-12-08 Metabolex, Inc. Triazoles substitués bicyliques comme modulateurs de ppar et méthodes de préparation
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
JP5191744B2 (ja) * 2005-02-25 2013-05-08 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖子活性化受容体デルタリガンドのチアゾール誘導体及びその製造方法
US7982050B2 (en) * 2005-05-07 2011-07-19 Seoul National University Industry Foundation Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EP1916234B1 (fr) * 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Composé d'acide cyclopropanecarboxylique
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
EP1999098A2 (fr) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Nouveaux composés, leur préparation et utilisation
CA2662305C (fr) 2006-09-07 2012-04-17 Amgen Inc. Modulateurs heterocycliques du recepteur couple a la proteine g (gpr40)
EP2061760A1 (fr) 2006-09-07 2009-05-27 Amgen, Inc Composés benzo-fusionnés destinés à être utilisés dans le traitement de troubles métaboliques
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
AU2008338963A1 (en) * 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use
WO2009086277A1 (fr) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Benzènes tétrasubstitués
WO2009111056A1 (fr) 2008-03-06 2009-09-11 Amgen Inc. Dérivés d'acide carboxylique conformationnellement dépendants, utiles dans le traitement de troubles du métabolisme
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
CN102781924A (zh) * 2010-02-25 2012-11-14 首尔大学校产学协力财团 用作过氧化物酶体增殖剂激活受体的配体的硒唑衍生物、其制备方法及其化合物的用途
WO2015035171A1 (fr) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
RU2174121C2 (ru) * 1996-08-19 2001-09-27 Джапан Тобакко Инк. Производные пропионовой кислоты и фармацевтическая композиция на их основе
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
DE60216094T2 (de) * 2001-06-07 2007-06-06 Eli Lilly And Co., Indianapolis Modulatoren der peroxisom-proliferator-aktivierten rezeptoren (ppar)

Also Published As

Publication number Publication date
MXPA04007564A (es) 2004-11-10
CO5601012A2 (es) 2006-01-31
ECSP045285A (es) 2004-10-26
KR20040091693A (ko) 2004-10-28
CA2478520A1 (fr) 2003-09-12
US20030207924A1 (en) 2003-11-06
ATE405260T1 (de) 2008-09-15
OA12780A (en) 2006-07-07
NO20044242L (no) 2004-10-06
IS7377A (is) 2004-07-29
EP1482935B1 (fr) 2008-08-20
AR038881A1 (es) 2005-02-02
JP2005528348A (ja) 2005-09-22
PA8567801A1 (es) 2003-11-12
AP2004003124A0 (en) 2004-09-30
ES2310650T3 (es) 2009-01-16
AU2003206059A1 (en) 2003-09-16
UY27695A1 (es) 2003-10-31
TW200305403A (en) 2003-11-01
PE20030989A1 (es) 2003-11-29
PL372969A1 (en) 2005-08-08
EP1482935A1 (fr) 2004-12-08
WO2003074050A1 (fr) 2003-09-12
BR0308277A (pt) 2004-12-28
ZA200406068B (en) 2005-09-06
HN2003000090A (es) 2004-05-05
TNSN04168A1 (fr) 2007-03-12
DE60323060D1 (de) 2008-10-02
EA200400943A1 (ru) 2005-02-24

Similar Documents

Publication Publication Date Title
MA27182A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar.
TNSN04168A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
MA27189A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA26688A1 (fr) 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
AU1850801A (en) The combination of a serotonin reuptake inhibitor and irindalone
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
FR08C0004I2 (fr) Composition orale d' une dose pour une libération prolongée
MA30231B1 (fr) Derives de benzamides et d'heteroarenes
MA26954A1 (fr) ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES
MA26997A1 (fr) Derives de 3-(4-amidopyrrole-2-ylmethylidene)-2-indolinone utilisables comme inhibiteurs de proteine-kinases
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA27135A1 (fr) Agents antidiabetiques oraux
PT1003725E (pt) Fungicidas de fluoropirazoldifenilamidas
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA27141A1 (fr) DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
SE9903997D0 (sv) New compounds
AU5499701A (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
WO1999012570A3 (fr) Procede, compositions et trousses servant a augmenter la biodisponibilite orale d'agents pharmaceutiques